The use of intravitreal injections (IVIs) of steroidal and vascular endothelial growth factor (VEGF) antagonists has dramatically increased due to the widening spectrum of indications for its use, such as age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), macular edema following retinal vein occlusion (RVO), and choroidal neovascularization (CNV) related to other diseases. This evidence concerns the gene VEGFA and macular retinal edema.